Abstract: The present invention relates to ophthalmic preparations in the form of eyedrops based on BDNF (Brain-Derived Neurotrophic Factor). Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.

Abstract: The present invention relates to ophthalmic preparations in the form of eyedrops based on PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) which restore the normal visual function in retinal dystrophy/retinopathy and optic neuropathy, with special reference to glaucoma. Said preparations can be administered topically to the intact eye surface, and are useful in the treatment of various forms of retinal dystrophy/retinopathy and optic neuropathy, such as glaucoma.

Abstract: The invention concerns ophthalmic solutions indicated for use as tear substitutes, containing a combination of hyaluronic acid and a polysaccharide known as TSP (Tamarindus indica Seed Polisaccharide) which are able, when administered together in a combination, to act synergistically in stimulating the return to normality of the conjunctival mucosa affected by dry eye syndrome, thus inducing a remarkable improvement in the number and morphology of the conjunctival microvilli. The ophthalmic preparations, proposed for use in the treatment of dry eye syndrome contain, in combination, from 0.05 to 2% by weight of tamarind seed polysaccharide (TSP) and from 0.05 to 1% by weight of hyaluronic acid in aqueous solution.

Abstract: Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.

Abstract: The invention concerns ophthalmic solutions indicated for use as tear substitutes, containing a combination of hyaluronic acid and a polysaccharide known as TSP (Tamarindus indica Seed Polisaccharide) which are able, when administered together in a combination, to act synergistically in stimulating the return to normality of the conjunctival mucosa affected by dry eye syndrome, thus inducing a remarkable improvement in the number and morphology of the conjunctival microvilli. The ophthalmic preparations, proposed for use in the treatment of dry eye syndrome contain, in combination, from 0.05 to 2% by weight of tamarind seed polysaccharide (TSP) and from 0.05 to 1% by weight of hyaluronic acid in aqueous solution.